MeiraGTx Holdings PLC (MGTX)vsRegeneron Pharmaceuticals Inc (REGN)
MGTX
MeiraGTx Holdings PLC
$9.71
-0.46%
HEALTHCARE · Cap: $884.56M
REGN
Regeneron Pharmaceuticals Inc
$818.77
+0.68%
HEALTHCARE · Cap: $81.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 3808% more annual revenue ($15.53B vs $397.50M). REGN leads profitability with a 27.9% profit margin vs 19.9%. MGTX trades at a lower P/E of 10.7x. REGN earns a higher WallStSmart Score of 66/100 (B-).
MGTX
Buy61
out of 100
Grade: C+
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MGTX.
Margin of Safety
+42.1%
Fair Value
$1389.86
Current Price
$818.77
$571.09 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Strong operational efficiency at 76.0%
Revenue surging 8609.0% year-over-year
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : MGTX
The strongest argument for MGTX centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 19.9% and operating margin at 76.0%. Revenue growth of 8609.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : MGTX
The primary concerns for MGTX are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
MGTX carries more volatility with a beta of 1.35 — expect wider price swings.
MGTX is growing revenue faster at 8609.0% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (66/100 vs 61/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MeiraGTx Holdings PLC
HEALTHCARE · BIOTECHNOLOGY · USA
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?